Email this article Supplementary appendix
- Issue: Vol 18, No 2 (2022)
- Pages: 229-251
- Section: EDITORIAL
- Published: 15.08.2022
- URL: https://oncourology.abvpress.ru/oncur/article/view/1612
- ID: 1612
Cite item
Full Text
Abstract
This appendix formed part of the original submission and has been peer reviewed.We post it as supplied by the authors. Supplement to: Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol 2022; published online April 27. https://doi.org/10.1016/S1470-2045(22)00212-1.
References
Supplementary files
